Erica Schleifman

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Travis Clark, Jon Chung, Mark Kennedy et al. · Journal of Molecular Diagnostics · 2018 · 201 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail et al. · Nature Medicine · 2022 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters, Rafał Dziadziuszko, Alessandro Morabito et al. · Nature Medicine · 2022 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17

Nanoparticles Deliver Triplex-forming PNAs for Site-specific Genomic Recombination in CD34+ Human Hematopoietic Progenitors

Nicole McNeer, Joanna Chin, Erica Schleifman et al. · Molecular Therapy · 2010 · 97 citations · Full text

Pharmacy, Biotechnology, Molecular Biology +17